Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue: +30.2%
EPS: −22.3%
Free cash flow: +137.8%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

300.31 0.06 +0.02%

Follow KRYS

Alert me

Market cap: $8.9B
P/E: 39.2×
Fwd P/E: 45.7×
Dividend yield: —
F-score: 7/9
Altman Z: 39.03
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Krystal Biotech, Inc. 10-K filed Feb 17, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed Feb 17, 2026 · accepted 7:05 AM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 19, 2025: 20 added · 62 removed · 59 modified; 7 with only figures updated; 2 moved without change

Krystal Biotech, Inc. 10-K filed Feb 17, 2026

What changed

Stockrow Weekly